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Abstract: Diabetes mellitus is a metabolic disease characterized by chronic hyperglycemia that induces
other pathologies including diabetic retinopathy and bone disease. Adult Danio rerio (zebrafish)
represents a powerful model to study both glucose and bone metabolism. Then, the aim of this study
was to evaluate the effects of liquiritigenin (LTG) on blood glucose level and diabetes complications
in hyperglycemic adult zebrafish. LTG is a flavonoid extracted from Glycyrrhiza glabra roots which
possess important antioxidant, anti-inflammatory, and anti-diabetic properties. During four weeks of
glucose treatment, LTG significantly prevented the onset of the hyperglycemia in adult zebrafish.
Moreover, hyperglycemic fish showed increased advanced glycation end-products (AGEs) and
parathormone levels whereas LTG completely prevented both of these metabolic alterations. Large
bone-loss areas were found in the scales of glucose-treated fish whereas only small resorption lacunae
were detected after glucose/LTG treatment. Biochemical and histological tartrate resistant acid
phosphatase (TRAP) assays performed on explanted scales confirmed that LTG prevented the increase
of osteoclastic activity in hyperglycemic fish. The osteoblastic alkaline phosphatase (ALP) activity was
clearly lost in scales of glucose-treated fish whereas the co-treatment with LTG completely prevented
such alteration. Gene expression analysis showed that LTG prevents the alteration in crucial bone
regulatory genes. Our study confirmed that LTG is a very promising natural therapeutic approach
for blood glucose lowering and to contrast the development of bone complications correlated to
chronic hyperglycemia.
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1. Introduction
Diabetes mellitus is a metabolic disease characterized by chronic hyperglycemia and impaired
insulin secretion or action. Diabetes is one of the major pathological problem of our society because
it is associated with highly severe long-term health complications. In fact, chronic hyperglycemia
affects a large variety of organs inducing several secondary pathologies including retinopathy and
bone alterations [1].
Liquiritigenin (LTG) is a licorice-derived flavonoid (from Glycyrrhiza glabra) that is already
tested in in vitro and in vivo models for treating many diseases, including diabetes [2,3]. LTG,
known for its anti-inflammatory, anti-hyperlipidemic, and antioxidative properties, has already been
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recognized as an optimum treatment to attenuate diabetic complications derived from hyperglycemia.
It has been demonstrated in vitro that LTG protects glomerular mesangial cells (HBZY-1) from high
glucose-induced extracellular matrix accumulation, oxidative stress, and the inflammatory response
by reducing the production of interleukin 1β (IL1β), interleukin 6 (IL-6), and activation of nuclear
factor-kappa B (NF-kB) and nod-like receptor protein 3 (NLRP3) [4]. In vivo studies confirmed its
anti-diabetic activity; for example, studies performed on streptozocin-induced diabetic mice have
shown that LTG and isoliquiritigenin have a glucose-lowering effect measured through oral glucose
tolerance test and also induce a reduction of triglycerides [2,5].
The mechanisms by which type 2 diabetes mellitus (T2DM) induces bone alterations are still
debated and not completely clarified but it is well known that hyperglycemia affects bone health in
many ways inducing fragility, mechanical strength reduction, impaired bone matrix microstructure,
and altered bone cell function, leading to osteoporosis and increased risk of fractures [6,7]. In fact,
hyperglycemia leads to hypocalcemia by increasing urinary calcium excretion, impairing the vitamin D
status, and interfering with the parathyroid hormone (PTH) and vitamin D axis, moreover, it induces
a chronical inflammatory state [8]. High blood glucose levels increase the formation of advanced
glycation end-products (AGEs) that are a source of reactive oxygen species (ROS) and that directly
damage bone extracellular matrix by creating irreversible cross-links between the collagen type 1
fibers [9]. Moreover, some of the antidiabetic agents, such as thiazolidinediones, can negatively affect
bone metabolism through alterations of the transcriptional regulation [6].
LTG is a very promising anti-diabetes therapeutic agent not only for its glucose-lowering activities
but also because of its effects on bone metabolism. It has been reported that LTG has beneficial effects
on osteoblast activity and bone mineralization process in several in vitro studies. In fact, LTG increases
osteoblasts growth, enhances alkaline phosphatase (ALP) activity, collagen synthesis, and significantly
reduces ROS production and osteoclasts differentiation through the modulation of tumor necrosis factor
α (TNFα), IL-6, and receptor activator of nuclear-kB ligand (RANKL) [10]. Furthermore, our recent
study, performed in adult zebrafish glucocorticoid-induced osteoporosis (GIOP) model, highlights
the LTG effects in counteracting the osteoporotic complication related to glucocorticoid treatment
(Carnovali M, Banfi G, Mariotti M.; unpublished material).
Then, the aim of this study was to test LTG as a possible natural therapeutic and preventive agent
for diabetic complications in zebrafish T2DM model focusing on diabetes-induced bone disease.
2. Materials and Methods
2.1. Ethic Statement
This experimentation has been performed in the Zebrafish Laboratory (IRCCS Galeazzi/GSD
Foundation, Milan, Italy) according to the Italian and European guidelines on research (EU Directive
2010/63/EU). Zebrafish experimentation and all protocols of this study were approved by the Italian
Ministry of Health (authorization No.349/2017-PR).
2.2. Animals
Adult Danio rerio of AB strain were maintained under standard conditions [11] in a ZEBTEC©
bench top system (Tecniplast, Buguggiate, Italy). The treatments have been performed maintaining
fish in E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4) solution at 28 ◦C.
2.3. Chemicals
Both D-(+)-glucose and liquiritigenin (7,4′-Dihydroxyflavanone, LTG) have been purchased by
Sigma-Aldrich. Glucose have been dissolved in E3 medium while LTG was initially dissolved in
dimethyl sulfoxide (DMSO, Sigma-Aldrich, St. Louis, Missouri, USA) then diluted in E3 medium,
with or without glucose, to have the final concentration of 1 nM.
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2.4. Adult Treatments and Samples Collection
Zebrafish diabetic model has been generated through immersion in E3 medium 4% glucose
solution following our previously published protocol [12] while non-diabetic fish has been maintained
in E3 medium only. In order to study LTG effects, both glucose and non-glucose-treated fish have
been treated with 1 nM LTG for all the 4 weeks of experimentation. This LTG concentration has been
identify in another study (Carnovali M, Banfi G, Mariotti M.; unpublished material) since it has shown
biological activity useful to counter the effects of glucocorticoid-induced osteoporosis.
At the end of the treatment, samples have been collected as described in our previously published
paper [12]. Briefly, fish were euthanized and blood collection was performed according to a previously
published protocol [13]. Basal glycemia measurement was performed according to previously published
protocols [13,14] using a glucometer (Freestyle Lite, Abbott, Alameda, CA, USA), the remaining collected
blood was pooled and used to quantify advanced glycosylation end products (AGEs) and parathormone
(PTH) through ELISA tests (Fish Hemoglobin-Advanced glycosylation End Products ELISA Kit and
Fish Parathormone Intact ELISA Kit, MyBioSource, Santiago, CA, USA) according to manufacturer’s
protocols. Scales have been carefully removed from both sides of the fish body operating using
Dumont® Stainless steel forceps (Sigma Aldrich) under a light stereomicroscope (Olympus SZX-ZB7)
and have been processed differently depending on the test to be performed, as described below.
2.5. Bone Matrix Vital Staining
At the end of the treatment, fish were live stained overnight using a 0.005% calcein
(Bis[N,N-bis(carboxymethyl)aminomethyl]fluorescein, Sigma Aldrich) E3 solution [12]. Then, after
removal as previously described, scales were fixed using 3.5% formaldehyde 0.1 M sodium phosphate
buffer solution. Images were acquired and analyzed using a fluorescence microscope (Olympus
SZX-ZB7) equipped with Discovery CH30 camera (TiEsseLab, Milano, Italy).
2.6. Histological TRAP and ALP Scale Assays
Histological tartrate resistant acid phosphatase (TRAP) assay were performed directly on
explanted scales using Leukocytes acid phosphatase (TRAP) detection kit (Sigma Aldrich) following
the manufacturer’s protocol. Histological ALP assay was performed using BCIP®/NBT liquid substrate
(Sigma Aldrich) according to manufacturer’s protocol.
2.7. Biochemical TRAP and ALP Scale Assays
Biochemical TRAP and ALP activities were evaluated on explanted scales following previously
published methods [15,16]. To perform both these analyses, absorbance was read at 405 nm using a
spectrophotometer (iMarkTM Microplate Reader, Bio-Rad, Hercules, CA, USA).
2.8. Gene Expression Analysis
Euroclone GOLD total RNA kit (Euroclone, Milano, Italy) was used to isolate total RNA of
the explanted zebrafish scales, then Euroscript M-MLV reverse Transcriptase kit (Euroclone, Milano,
Italy) was used to perform the complementary DNA (cDNA) synthesis. cDNA was used to perform
quantitative real-time PCR (qPCR) to analyze bone metabolism marker genes such as tumor necrosis
factor receptor superfamily member 11b (tnfrsf11b, fish homolog of human osteoprotegerin), tumor
necrosis factor (ligand) superfamily member 1B (tnfrsf1b, fish homolog of human rank), and tumor
necrosis factor (ligand) superfamily member 11 (tnfsf11, fish homolog of human rankl). qPCR was
performed using StepOneTM Real-time PCR system (Applied Byosystems, Foster City, CA, USA) using
Fluocycle IITM SYBR® Master Mix (Euroclone, Milano, Italy). Gene primers and the amplification
conditions were previously published [17]. Each qPCR analysis was run in triplicate. The values of
target messenger RNA (mRNA) expression were calculated from the target threshold cycle values and
βactin mRNA level was used as standard curve.
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2.9. Statistics
Three fish were tested for each treatment (control, 4% glucose, LTG and 4% glucose plus LTG)
and the entire experiment was repeated three times with comparable results. Data concerning basal
glycemia at the 28th day of treatment refers to the mean of six glycemia fish; the remaining blood was
used to perform ELISA tests. Data concerning scale biochemical analysis of ALP and TRAP activity
were derived from 20 scales for each tested fish, while histological analysis refers to 50 scales for fish.
qPCR analysis was repeated three times with comparable results and each qPCR analysis was run in
triplicate. Data are expressed as mean ± standard deviation. Statistical significance per p-values were
set using one-way analysis of variance (ANOVA) followed by Bonferroni test. All significance values
were set at less than p < 0.05 (*), p < 0.01 (**) and p < 0.001 (***).
3. Results
3.1. Liquiritigenin Decreases Blood Alterations in Hyperglycemic Zebrafish Model
Adult fish were treated with 4% glucose solution for four weeks. Glucose treatment induced basal
hyperglycemia, whose average results were equal to 137 mg/dL after 28 days of treatment (Figure 1A,
+175% vs. CTR). Further, 1 nM LTG treatment partially prevented the onset of the hyperglycemia,
reducing basal glycemia to 73, only 48% higher that CTR levels. Moreover, diabetic fish showed
increased PTH (Figure 1B) and AGEs (Figure 1C) levels and LTG completely prevented both of these
alterations, maintaining levels equal to normal ones.
Figure 1. (A) Basal blood glucose measurement. Fish treated with glucose (GLU) were compared to
control fish (CTR), LTG-treated fish (LTG), and glucose/LTG (GLU + LTG) co-treated fish (CTR vs.
GLU p < 0.001, LTG vs. GLU p < 0.001, GLU + LTG vs. GLU p < 0.001). Parathormone (PTH) (B) and
advanced glycation end-products (AGEs) (C) dosage in fish blood. Blood level of AGEs and PTH of
glucose-treated fish (GLU) were compared to control (CTR) and glucose/LTG-treated (GLU + LTG) fish
(CTR vs. GLU, p < 0.001; GLU + LTG vs. GLU, p < 0.001). p < 0.01 (**) and p < 0.001 (***).
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3.2. Liquiritigenin Treatment Reduces Bone Loss in Glucose-Treated Fish
In order to evaluate liquiritigenin effects on hyperglycemia-induced bone loss, we performed
calcein vital staining on explanted scales. Great resorption lacunae (Figure 2A, white arrows) were
evident on glucose-treated scale border whereas only small resorption lacunae were detected on
glucose/LTG co-treated scales. Moreover, we quantified the mineralized area of the scales using
imaging software tools, evidencing that the glucose-dependent reduction of 15.2% was significantly
prevented by LTG treatment (Figure 2B). LTG alone did not show any effect on scale bone matrix.
Figure 2. (A) Calcein vital staining of fish scales. The mineralized tissue profile can be observed in
untreated (CTR) scales or treated with LTG, glucose, and GLU + LTG. Mineralized matrix resorption
lacunae are indicated by white arrows. (B) Quantification of mineralized area of the scale (CTR vs.
GLU, p < 0.001; GLU + LTG vs. GLU, p < 0.001). p < 0.001 (***).
3.3. Liquiritigenin Prevents Osteoclast Activation in Glucose-Treated Fish
In order to evaluate the catabolic osteoclast activity, histological and biochemical TRAP assays
were performed directly on the explanted scales. Histological TRAP staining evidenced an intense
signal along the scale border of glucose-treated fish scales and a significantly reduced TRAP activity
on scales from fish treated with both glucose and LTG (Figure 3A). In fact, LTG treatment reduced the
percentage of TRAP-positive scales (from 95% to 38%, Figure 3B) and the size of resorption lacunae,
measured as percentage of resorbed scale circumference (from 31% to 4.5%, Figure 3C), with respect
to glucose-treated fish. Biochemical TRAP assay performed on explanted scales confirmed that LTG
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treatment prevented the increase of TRAP activity in hyperglycemic fish (Figure 3D). LTG alone did
not perturb normal osteoclastic activity.
Figure 3. (A) Histological TRAP activity assay. Enzymatic activity along scale border of CTR scales
or treated with LTG, GLU, and GLU + LTG can be visualized by violet staining. (B) Percentage of
TRAP-positive scales (CTR vs. GLU, p < 0.001) (GLU + LTG vs. GLU, p < 0.001). (C) TRAP-activity
extension calculation among TRAP-positive scales, (CTR vs. GLU, p < 0.001) (GLU + LTG vs. GLU,
p < 0.001). (D) Biochemical TRAP assay. Quantification of TRAP activity was performed on same
samples with a biochemical assay (CTR vs. GLU, p < 0.001; GLU + LTG vs. GLU, p < 0.001). p < 0.01 (**)
and p < 0.001 (***).
3.4. Liquiritigenin Treatment Prevents the Reduction of Alkaline Phosphatase Activity in Hyperglycemic Fish
In order to evaluate the anabolic osteoblast activity, histological and biochemical ALP assays were
performed directly on the explanted scales. In the histological assay, the ALP signal was clearly lost in
scales from glucose-treated fish whereas the co-treatment with LTG was able to completely prevent
such alterations (Figure 4A). These data were confirmed by the biochemical analysis that showed a
reduction of 32% ALP activity in glucose-treated scale, whereas in the presence of LTG, the reduction
is limited to 6% (Figure 4B).
Figure 4. (A) Histological ALP activity assay. Enzymatic ALP activity of CTR scales or treated with
LTG, GLU, and GLU + LTG can be visualized as blue staining. The areas of fish scale with a reduced
ALP activity are evidenced by black arrows. (B) Biochemical ALP assay. Quantification of ALP activity
was performed on same samples with a biochemical assay (CTR vs. GLU, p < 0.001) (GLU + LTG vs.
GLU, p < 0.01). p < 0.01 (**) and p < 0.001 (***).
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3.5. Liquiritigenin Treatment Prevents the Alteration of Bone Regulatory Genes in Hyperglycemic Fish
The expression analysis of genes involved in the regulation of bone tissue was done by real-time
PCR in the scales after treatment with glucose and/or LTG (Figure 5). Tumor necrosis factor receptor
superfamily, member 11b tnfrsf11b (fish homolog of human osteoprotegerin), and tumor necrosis factor
(ligand) superfamily member 11 tnfrsf11 (fish homolog of human rankl), two important regulators of
osteoclast differentiation, were found decreased in the scales of hyperglycemic fish, whereas tumor
necrosis factor receptor superfamily member 1B tnfrsf1b (fish homolog of human rank) resulted in being
not modulated. LTG co-treatment restored, in the GLU-treated fish, the expression level found in CTR
and LTG alone.
Figure 5. qPCR analysis of bone marker genes. Bone markers related to bone metabolism have
been analyzed: Tumor necrosis factor receptor superfamily member 11b (tnfrsf11b, homolog of
osteoprotegerin OPG), tumor necrosis factor receptor superfamily member 1B (tnfrsf1b, homolog of
RANK), and tumor necrosis factor (ligand) superfamily member 11 (tnfsf11, homolog of RANKL).
(CTR vs. GLU, p < 0.001). p < 0.001 (***).
4. Discussion
The anti-inflammatory effect of LTG has been widely documented through several studies that
highlights its role in the modulation of pro-inflammatory cytokines such as IL-1β and IL-6 [18].
Because of very promising in vitro and in vivo studies in diabetic-related bone disease, LTG can be
considered a potential candidate to develop a new therapeutic approach against diabetes-related
effects [19,20]. LTG tested in our T2DM zebrafish model confirms its ability to contrast the onset of
basal glycemia after glucose treatment. In fact, a similar effect has been previously reported in vivo
in streptozocin-nicotinamide diabetic mice during oral glucose tolerance test [2,5]. As expected in a
diabetes animal model, we detected a significant increase of AGEs in the blood of hyperglycemic fish
by ELISA and co-treatment with LTG was able to suppress AGEs generation suggesting its potential
ability to reduce hyperglycemia-induced complications.
The chronic hyperglycemia in diabetic patients promotes AGEs generation that, in turn, induces
cellular dysfunction and other tissue damages by acting on their receptor RAGE (receptor for AGE) [21].
About diabetes complications, glycemia and AGEs have been positively associated with bone
turnover in older men, with increasing incidence of hip fracture [22,23].
We can hypothesize that the increase of AGEs can contribute to bone loss induction in our model
of hyperglycemic zebrafish. Several alternative therapeutic approaches against AGEs in diabetes
patients are currently being studied, including the use of natural molecules [24]. The capacity of LTG
to contrast the generation of AGEs and bone loss phenotype is pivotal to further understand if this
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molecule is able to prevent other diabetes-related complications such as retinopathy, nephropathy,
and neuropathy.
We also detected a significant increase of PTH level in the blood of hyperglycemic fish by
ELISA assay. The hormonal regulation of calcium metabolism is crucial in human bones and the
PTH pathway plays an important role [25]. It has been demonstrated that high levels of PTH can
directly affect osteoclast activity leading to an increased bone resorption [26]. There are conflicting
data concerning PTH role in the glucose homeostasis but most studies agree that impaired glucose
metabolism is associated with elevated PTH levels and that there is a correlation between PTH and
insulin resistance [27]. These data support the idea that an increase of PTH levels in hyperglycemic fish
can represent a positive stimulus for osteoclast activation. The effect of LTG in lowering PTH level may
represent additional evidence of the anti-osteoporotic activity of LTG. In fact, in our zebrafish model,
we correlated the anti-diabetic properties of LTG to the ability to maintain the normal bone metabolism
in fish scales. As previously described [12], hyperglycemia is correlated to a highly significant increase
of osteoclast activity and decrease of osteoblast activity that led to an osteoporotic phenotype in adult
fish scales. LTG has already been reported to have positive effects on osteoblasts activity and on the
reduction of osteoclast differentiation in vitro [10]. Studies performed on MC3T3-E1 cells showed
that LTG promotes their osteoblast differentiation dose-dependently acting on the Smad1/5-dependet
pathway, increases ALP activity, collage synthesis, and their mineralization. [28,29].
A study performed on RANKL-stimulated RAW-D cells induced to differentiate osteoclasts
highlights that LTG inhibits both the formation of mononuclear and multinuclear osteoclasts and
impairs the bone resorption activity of BMM-derived osteoclasts. Moreover, LTG has been reported to
decrease osteoclasts differentiation factors such as TNFα, IL-6, and RANKL [10].
Moreover, we recently reported important effects of LTG in counteracting the bone-loss phenotype
in zebrafish GIOP model (Carnovali M, Banfi G, Mariotti M.; unpublished material). LTG treatment in
T2DM model can sensitively reduce the onset of the osteoporosis phenotype, contrasting the osteoclast
activation and protecting osteoblast activity. It is known that high-glucose microenvironment can
stimulate an inflammatory status with increased production of cytokines, AGEs, and ROS, which are
able to induce osteoclastogenesis [30]. Recent studies on implant cores evidenced that bone formation
activities by osteoblasts were suppressed in the presence of elevated AGEs, which ultimately results in
the development of bone loss [31].
Regarding the molecular mechanism of LTG protective effects on hyperglycemic-induced bone loss,
the gene expression analysis suggested that LTG suppresses the reduction of osteoclastogenesis-inhibitor
factor tnfrsf11b (osteoprotegerin) and tnfsf11 (rankl). Further studies will be involved in the analysis
of inflammatory and oxidative stress pathways in hyperglycemic fish and the role of LTG as
therapeutic modulator.
5. Conclusions
LTG treatment in hyperglycemic fish is able to improve blood glucose clearance preventing the
generation of AGEs and the alteration of calcium metabolism (PTH pathway). In this way, bone
turnover and resorption cannot be activated, maintaining the normal equilibrium of bone metabolism
in the scales.
Our study confirmed that LTG is a very promising natural therapeutic approach for blood glucose
lowering and to contrast the development of bone complications correlated with chronic hyperglycemia.
Further studies will evaluate the effect of LTG in preventing other diabetes-related complications such
as retinopathy, nephropathy, and neuropathy.
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